3 Comments

Hence ebitda growth CAGR could be the future returns. Less chances of derating unless some major wrong capital allocation

Expand full comment

Multiple is fairly priced for current profits.

Expand full comment

Great article highlighting past performance and efficiency metrics wrt peers. For valuations maybe a brief projection on growth of new hospital revenues and moderate growth of existing needs to be done. With regards to current valuation, it's fairy priced since they have achieved scale.

Expand full comment